- Title
- Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)
- Creators
- Christine E. Ryan - Dana-Farber Cancer InstituteJennifer L. Crombie - Dana-Farber Cancer InstituteSvitlana Tyekucheva - Dana-Farber Cancer InstituteMikaela M. McDonough - Dana-Farber Cancer InstituteJosie S. Montegaard - Dana-Farber Cancer InstituteAustin I. Kim - Dana-Farber Cancer InstituteJacob D. Soumerai - Massachusetts General HospitalAlvaro J. Alencar - Sylvester Comprehensive Cancer CenterShruti Bhandari - Eastern Maine Medical CenterDavid C. FisherJennifer R. Brown - Dana-Farber Cancer InstituteMatthew S. Davids - Dana-Farber Cancer Institute
- Publication Details
- Blood, Vol.140(Supplement 1), pp.9871-9872
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- Record Identifier
- 991031786571902976
Journal article
Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)
Blood, Vol.140(Supplement 1), pp.9871-9872
2022-11-15
Metrics
1 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.130 Lymphomas
- 1.130.1170 Chronic Lymphocytic Leukemia
- Web Of Science research areas
- Hematology
- ESI research areas
- Clinical Medicine
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites